Sign inJoin waitlistJoin the waitlist

Ivy Abraham

Clinical Associate of Medicine · University of Chicago Medical Center

Credentials: · · · · ·

History

UChicago Medicine
2020–Present

Hematology and Medical Oncology
University of Illinois College of Medicine at Chicago
2014–2017
Internal Medicine
University of Illinois College of Medicine at Chicago
2014–2017
University of Illinois College of Medicine
2010–2014

Research

High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease
Neurology · 2009 · 335 citations
Region of interest template for the human basal ganglia: comparing EPI and standardized space approaches
NeuroImage · 2008 · 95 citations
Structural racism is a mediator of disparities in acute myeloid leukemia outcomes
Blood · 2022 · First of 23 authors · 88 citations

Anand Patel
6 papers · 1 as a fellow
Irum Khan
6 papers
AD
Ami Dave
5 papers · 3 as a fellow
Jessica Altman
5 papers
Madelyn Burkart
5 papers · 5 as a fellow
Maryam Zia
5 papers
Melissa Larson
5 papers
Stephanie Tsai
5 papers
Wendy Stock
5 papers
Amani Erra
4 papers
AA
Ahmed Aleem
3 papers · 3 as a fellow
Mylene Remo
3 papers · 2 as a fellow

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033